

2 **Senate Bill No. 296**

3 (By Senators Minard, Snyder, Prezioso,  
4 Unger, Boley and K. Facemyer)

5 \_\_\_\_\_  
6 [Introduced January 27, 2011; referred to the Committee on Health  
7 and Human Resources; and then to the Committee on the Judiciary.]  
8 \_\_\_\_\_

9  
10 A BILL to amend and reenact article 9, chapter 64 of the Code of  
11 West Virginia, 1931, as amended, relating to authorizing the  
12 Board of Optometry to promulgate a legislative rule relating  
13 to oral pharmaceutical prescriptive authority.

14 *Be it enacted by the Legislature of West Virginia:*

15 That article 9, chapter 64 of the Code of West Virginia, 1931,  
16 as amended, be amended and reenacted to read as follows:

17 **ARTICLE 9. AUTHORIZATION FOR MISCELLANEOUS AGENCIES AND BOARDS TO**  
18 **PROMULGATE LEGISLATIVE RULES.**

19 **§64-9-1. Board of Optometry.**

20 The legislative rule filed in the state register on the  
21 thirtieth day of July, two thousand ten, authorized under the  
22 authority of section six, article eight, chapter thirty, of this

1 code, modified by the Board of Optometry to meet the objections of  
2 the Legislative Rule-Making Review Committee and refiled in the  
3 state register on the third day of January, two thousand eleven,  
4 relating to the Board of Optometry (oral pharmaceutical  
5 prescriptive authority, 14 CSR 2), is authorized with the following  
6 amendments:

7 On page three, subsection 9.2, by striking the period  
8 inserting a comma and adding the following, "and include hands-on  
9 supervised clinical training.";

10 On page four, subsection 10.2, after the words "standards of"  
11 by inserting the words, "education and";

12 On page four, by adding a new subsection 10.3 to read as  
13 follows. "10.3 A new oral drug used for a new indication may not  
14 be started on a patient until discussed with the patient's  
15 osteopathic or allopathic physician, and documented in the  
16 patient's record, in order to identify and minimize potential  
17 adverse reactions and drug interactions.";

18 And,

19 On page four, by adding a new subsection 10.4 to read as  
20 follows. "10.4 If the patient does not have a primary care  
21 provider or refuses to provide written permission to report the  
22 oral drug(s) to his or her primary care provider the certificate

1 holder may provide a written statement to the patient regarding the  
2 oral drug(s) administered with instruction to the patient to give  
3 the listed information to his or her current primary care provider  
4 or any primary care provider they would choose to see in the  
5 future.”.

6  
7

8 NOTE: The purpose of this bill is to authorize the Board of  
9 Optometry to promulgate a legislative rule relating to Oral  
10 Pharmaceutical Prescriptive Authority.

11  
12 This section is new; therefore, strike-throughs and  
13 underscoring have been omitted.